天蝎散Ⅰ号方治疗缺血性中风恢复期临床观察

目的:观察天蝎散Ⅰ号方治疗缺血性中风恢复期的临床疗效。方法:64例缺血性中风恢复期患者随机分为治疗组与对照组各32例。对照组给予常规西药治疗加脑心通胶囊口服;治疗组给予常规西药治疗加天蝎散Ⅰ号方口服,治疗前后进行神经功能缺损程度评价。结果:两组临床疗效比较,治疗组总有效率(93.75%)优于对照组(75.00%),差异有统计学意义(P0.05);治疗前后两组血脂检测结果提示治疗组在改善血脂方面优于对照组(P0.05);治疗前后两组血液流变学的变化,提示治疗组在改善血液流变学方面明显优于对照组(P0.05);两组治疗后双侧颈动脉内膜-中层厚度及内膜斑块消退比较差异也有统计学意义(P0.05)。结论:天蝎散Ⅰ号方治疗缺血性中风恢复期的疗效显著。     

Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape

Liposomes were the first nanoscale drug to be approved for clinical use in 1995. Since then, the technology has grown considerably, and pioneering recent work in liposome-based delivery systems has brought about remarkable developments with significant clinical implications. This includes long-circulating liposomes, stimuli-responsive liposomes, nebulized liposomes, elastic liposomes for topical, oral and transdermal delivery and covalent lipid-drug complexes for improved drug plasma membrane crossing and targeting to specific organelles. While the regulatory bodies’ opinion on liposomes is well-documented, current guidance that address new delivery systems are not. This review describes, in depth, the current state-of-the-art of these new liposomal delivery systems and provides a critical overview of the current regulatory landscape surrounding commercialization efforts of higher-level complexity systems, the expected requirements and the hurdles faced by companies seeking to bring novel liposome-based systems for clinical use to market.     

Research and development of antibiotics: insights from patents and citation network

Introduction: Bacterial resistance to antibiotics develops at an alarming rate and leads to the increasing morbidity and health-care costs in recent years. However, the global research and development (R&D) of antibiotics has fallen behind the emergence and spread of bacterial resistance and the world is heading towards a ‘post-antibiotic era’. In this context, systematic understanding of the technology landscape and evolving process of antibiotic R&D may help to provide insights for discovering future antibiotics more rationally.

Areas covered: Patents and patent citations are broadly believed to be powerful tools in representing the technology advances and capturing technology flows. In all, 707 U.S. patents related to antibiotic R&D are collected and analyzed. Furthermore, patent citations are visualized by a network-based approach, while the inter-relationship between patented technologies on antibiotics is further revealed.

Expert opinion: The current dry pipeline of antibiotic development requires substantial awareness and political support. It is essential to build an attractive and supportive environment for investment. Thus, a new antibiotic business model is needed to chase the balance between the market-oriented investment and public health goals. Additionally, drug development targeting Gram-negative bacteria, especially resistant Gram-negative bacteria, demands attentions from stakeholders because of their unmet medical needs.     

峨眉山疗养因子对老年慢性失眠症的疗效观察

目的　观察峨眉山疗养因子对老年慢性失眠症的治疗作用。方法　７５ 例老年慢性失眠症患者用峨眉山疗养因子治疗,观察治疗前后的睡眠情况。结果　治疗后失眠症状明显改善,总有效率达９４ ．７ ％ 。结论　峨眉山疗养因子对慢性失眠症有良好的治疗作用。     

表观遗传与肿瘤代谢研究进展

表观遗传学主要关注DNA甲基化、组蛋白修饰、染色质重塑，以及非编码RNA等超越DNA序列的基因调控机制。表观遗传机制参与了个体发育、细胞命运决定和肿瘤发生等众多生物学过程。其中表观遗传信息以各种染色质修饰和高级结构的形式存储于基因组中，它的建立和维持与细胞代谢紧密相关。肿瘤细胞中存在的代谢改变包括有氧糖酵解、葡萄糖摄取量增加、谷氨酰胺代谢异常活跃、利用非主要供能物质供能等，这些改变满足了肿瘤发生发展过程中旺盛的能量和物质需求，帮助细胞适应缺氧的肿瘤微环境，进而为肿瘤增殖、侵袭、迁移等生物活动提供支持。肿瘤细胞的表观遗传修饰与代谢之间存在复杂的相互关系，一方面肿瘤细胞中的代谢产物作为表观修饰酶的辅因子、修饰供体或拮抗分子影响表观修饰景观；另一方面表观遗传修饰可以直接改变代谢酶和转运蛋白的表达或通过影响信号转导和转录因子的表达调控细胞代谢。本文综述了不同表观遗传学过程与肿瘤细胞代谢之间的相互作用，并展望两者在肿瘤治疗中的潜在应用前景。     

益气活血通脑方治疗恢复期缺血性中风疗效观察

目的 观察自拟益气活血通脑方治疗恢复期缺血性中风的临床疗效。方法 110例恢复期缺血性中风患者随机分为两组,治疗组60例采用益气活血通脑方治疗,对照组50例口服吡拉西坦片治疗,疗程均为8周。结果 治疗组总有效率为90．00％,对照组总有效率为70．00％（P〈O．05）。结论 益气活血通脑方治疗恢复期缺血性中风疗效显著。     

中西医结合治疗恢复期脑梗死临床观察

目的：观察中药补阳还五汤加味与西医常规疗法合用治疗脑梗死恢复期的临床疗效。方法：将96例确诊的脑梗死恢复期患者随机分为治疗组50例和对照组46例,治疗组在对照组西医常规疗法基础上给予补阳还五汤加味治疗,每日l剂,2周为1个疗程。结果：治疗组愈显率和总有效率分别为78．00％和94．00％,对照组则分别为54．35％和80．43％,两组比较均有显著性差异（P〈0．05）。结论：补阳还五汤加味与西医常规疗法合用（中西医结合）可更有效地降低脑梗死的病残率。     

社区水平的多学科综合管理对脑梗死患者二级预防效果研究

目的 研究社区水平的多学科综合管理对恢复期脑梗死患者的二级预防效果。